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INVESTIGATION OF THE EFFECTS OF PIN1 INHIBITION IN 
HIPPOCAMPAL NEURONS 
SUMMARY 
Neurodegenerative process has been associated with aberrant cell cycle re-entry 
causing neuronal loss and impaired neurological functions. Despite of the 
progressively increasing mass of the data there is no single target or a treatment to 
overcome the disease. The evidence suggests that failure in neuronal cell cycle 
regulation, leading to apoptosis may play a significantly important role in the patho-
biological development of neurodegeneration. Many studies have reported that a 
wide range of cell cycle proteins such as Cyclin D, Cyclin A, Cyclin E, Cyclin B, 
Cdk4, PCNA, Cdc2 and Ki67, with the addition of some of cell cycle inhibitors 
including p16, p21 and p105 are elevated in neurons in the affected regions of late 
stage Alzheimer’s Disease patients, but not in same aged control individuals. 
Systemicaly, loss of neurological abilities often represent themselves in selective 
areas in nervous system. In the AD case the pathology primarily and initially affects 
the entorhinal cortex and hippocampus regions which are suggested to be more 
susceptible areas regarding AD pathology. 
Pin1(Peptidyl-prolyl cis/trans Isomerase) was the first human parvulin to be found 
and it has been observed to be essential for regulation of mitosis. It binds to and 
isomerizes the peptidyl–prolyl bond in specific phosphorylated Ser/Thr-Pro motifs, 
initiating conformational change in its target phosphoproteins. Being a 
phosphorylation signaling protein that regulates diverse cellular processes, Pin1 
deregulation may play a crucial role in the pathology of both AD and cancer, which 
makes it an attractive therapeutic target. Additionally, Pin1 knock-out animal model 
is the only one that can create age-dependent AD like pathology. Understanding the 
main role of Pin1 in cell cycle regulation holds significant importance in regard to 
elucidating the pathological behaviors of the disease and to develop certain 
therapeutic methods.  
This study aims to reveal the effects of Pin1 inhibition, by using its selective 
inhibitor juglone, on cell cycle marker proteins in hippocampal neurons. It also aims 
to demonstrate the effects of Pin1 inhibition on the structure of cytoskeleton and 
neuronal damage. The results indicate that inhibition of Pin1 in hippocampal 
neurons, activates and alters the expressional rates and cellular localization of cell 
cycle related marker proteins, also producing an AD like cellular pathology.   
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HĐPOKAMPAL NÖRONLARDA PĐN1 ĐNHĐBĐSYONUNUN HÜCRE 
DÖNGÜSÜ AKTĐVASYONUNA ETKĐSĐ 
ÖZET 
Son yıllarda yapılan araştırmalar, Alzheimer Hastalığı, Parkinson, Amiyotrofik 
Lateral Skleroz ve Frontotemporal Demans gibi nörodejeneratif hastalıkların, 
nöronlarda meydana gelen bazı mitotik anomalilerle ilişkili olduğunu göstermiştir. 
Gerçekleştirilen incelemeler, Alzheimer Hastalığı için özellikle hipokampal 
bölgedeki nöronların normalde bulundukları düşünülen G0 hücre döngüsü fazından 
çıkıp G1, S ve G2 fazlarına kadar ilerleyebildiklerini göstermiş ve bu durum 
hastalığın erken dönem patolojisi ile ilişkilendirilmiştir. Bu sonuçlar, ileri farklılaşma 
sebebiyle bölünme yeteneklerini kaybettikleri düşünülen nöronların mitotik 
potansiyelleri açısından merak uyandırıcıdır. Nöronlarda meydana gelen hücre 
döngüsü anomalilerinin anlaşılması sözü edilen nörodejeneratif hastalıkların 
moleküler patolojilerinin çözümlenmesinin yanı sıra nöronların rejenerasyon 
potansiyellerinin de anlaşılabilmesini olanaklı kılabilir. 
Nörodejenerasyondaki hücre bölünmesi sürecini başlatan ve kilit bir noktada 
bulunduğu düşünülen bu proteinlerden bir tanesi bir peptidil-prolil cis/trans izomeraz 
olan ve PPIaz protein ailesi üyesi olarak belirlenen Pin1’dir. Pin1 aynı zamanda 
tümör gelişiminde etkin olan molekülerin tespitine yönelik olarak yapılan 
çalışmaların öne çıkardığı proteinlerden birisi konumuna gelmiştir. Normal 
hücrelerdeki düzeyinden farklı olarak Pin1 proteininin, prostat, akciğer, göğüs ve 
beyin tümörleri gibi birçok tümörde yüksek düzeylerde eksprese edildiği tespit 
edilmiştir. Farklı kanser türlerindeki dikkat çekici yoğunluğu sebebiyle üzerine 
yapılan çalışmaların arttığı Pin1 proteininin; hücre içinde katalitik aktivasyon, 
protein-protein etkileşimleri, proteinlerin hücre içi lokalizasyonu gibi kritik 
noktalarda etkin olduğu ortaya çıkarılmış, bununla birlikte; büyüme, proliferasyon ve 
hücre yapısının stabilizasyonu gibi tümör gelişiminde etkili olan birçok protein ile 
etkileştiği gösterilmiştir. Pin1’in aynı zamanda nöronların G0 fazında kalmasından 
sorumlu nöroprotektif bir fonksiyonu olduğu düşünülmektedir. Bunlara ek olarak 
Pin1 knock-out fareler Alzheimer Hastalığı’nın moleküler patolojsini ürettiği 
belirlenen tek knock-out hayvan modelidir.   
Bu çalışma, Pin1 selektif inhibitörü olan juglone ile inhibisyonunun hipokampal 
nöronlarda, hücre döngüsü ile ilişkilendirilmiş belirteç proteinlere ve hücre 
morfolojisine etkisini incelemeyi amaçlamaktadır. Bunun yanı sıra Pin1’in juglone 
ile inhibisyonunun hücre iskeleti ve nöronal hasar üzerindeki etkilerinin ortaya 
konması amaçlanmıştır. Çalışmanın sonuçları Pin1 hipokampal nöronlarda inhibe 
edilmesinin hücre döngüsü ile ilgili marker genlerin ekspresyonunu artırdığı, bu 
proteinlerin subselüler lokalizasyonlarını etkilediği ve hücresel düzeyde 
nörodejeneratif bir patoloji oluşturduğunu göstermektedir. Pin1’in hücre döngüsü 
regülasyonundaki rolünün anlaşılması ve nörodejenerasyon ve kanser gibi hastalıklar 
ile ilişkisinin ortaya konması, bugüne kadar birbirinden farklı perspektiflerden 
değerlendirilmiş bu patolojilerin arasındaki moleküler bağlantının kurulması 
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açsısından ve bu uzantıda geliştirilecek olası terapötik açılımlara kaynaklık etme 
potansiyeli yüzünden önemlidir.     
 
 
 
 1
INTRODUCTION 
1.1 Purpose of the Thesis 
Abnormal cell cycle re-activation has recently been associated to varying types of 
neurodegeneration. Since there are many parameters already associated with 
neurodegenerative pathologies, it is extensively important to understand the 
chronology behind the pathology. According to the literature data, cell cycle re-
activation “response” is mainly an early event occurring in neurodegenerative 
conditions. In the Alzheimer’s Disease example, primary affected areas are the 
hippocampal and entorhinal regions of Central Nervous System (CNS) which were 
also at the focus of this study.   
Adult neurons were believed to be terminally differentiated; yet, according to some 
recent case reports and the literature data their capacity of re-entering cell cycle in 
CNS or in vitro remains to be existent. Therefore, the possibly false conclusion of 
differentiated neurons loose the capacity to divide and proliferate needs to be 
questioned again. It has been shown that regeneration of fully differentiated neurons 
requires some certain conditions that are still elusive. It is known that the presence of 
Neurobasal/FGF2 [1] or Ouabain [2] in the culture medium has an effect on 
regeneration of embryonic and adult hippocampal neurons in culture. On the other 
hand, intracellular signal transduction trafficking regarding the process remains 
unknown. Most strikingly, although the detected cell cycle markers in 
neurodegeneration prove the failed attempt in re-entering cell cycle and apoptosis, 
the data also suggests the attempt for limited replacement of neuronal loss related to 
the neurodegenerative pathology. 
Pin1, Peptidyl-prolyl cis/trans Isomerase (PPIase), is thought to be a neuroprotective 
protein that halts the neurons in G0 phase of cell cycle. Pin1 has also been associated 
to many signal transduction pathways related to cell cycle regulation and 
proliferation. Over-expression of Pin1 gene in mitotic cells is linked with cancer, 
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whereas down-regulation of it in CNS is associated with many neurodegenerative 
conditions.  
In this study, the effect of Pin1 inhibition in hippocampal neurons using a selective 
inhibitor, juglone, was investigated by observations of different cell cycle markers 
such as Cyclin D1, Cyclin A, Cyclin B1, Ki67 and a neurodegeneration marker 
phospho-tau by immunocytochemistry, Real-Time PCR, Western Blotting and 
immunohistochemistry techniques. Understanding the role of Pin1 in abnormal cell 
cycle re-entry in neurodegeneration is crucial in terms of finding a new target and a 
way of approach to the target for future therapeutic options. This is the first study 
showing evidence regarding the link between the activation of cell cycle genes and 
formation of neurodegeneration pathology through inhibition of Pin1 at protein level.                
1.2 Background  
1.2.1 Neurodegeneration  
Neurodegeneration is generally defined as the progressive loss of function and the 
structure of a group of neurons in various regions of the CNS. This causes the loss of 
some major neurological impairments such as memory deficits, impaired motor 
functions and orientation. Neurodegenerative diseases such as Alzheimer’s Disease 
(AD), Frontotemporal Dementia (FD), Parkinson’s Disease (PD) or Amyotrophic 
Lateral Sclerosis (ALS) have similar patho-biological features suggesting possible 
molecular links among them.  
Neuropathies are mainly associated with intra- and extra-cellular accumulation of 
misfolded proteins. Additionally, neurodegeneration can be effective in a wide range 
of levels comprising systemic dysfunctions down to anomalies in molecular 
interactions. Majorly governing pheonomena comprise abnormal protein dynamics 
related to the deficiency of the ubiquitin-proteosome and autophagy-lysosome 
systems, abnormal protein folding through erroneous cleavage, oxidative 
modification, mitochondrial dysfunction, dysfunction of neurotrophins, overactive 
autoimmune processes, protein function through hyperphosphorylation and 
disruptions of axonal transport.  
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Neurodegenerative disorders represent themselves with their known genetic 
mechanisms as in familial forms of the diseases or with their components of 
misfolded or accumulated proteins. Importantly, many patho-biological similarities 
have been shown to lie in the core of “neurodegeneration”  [3-4] producing very 
similar pathological features [5]. Systemically, loss of the abovementioned 
neurological activities often represent themselves in selective areas in nervous 
system. For instance AD primarily and initially affects the entorhinal cortex and 
hippocampus, while PD takes place in the substantia nigra progressively diminishing 
the main function of the region. 
Through the history of neurogeneration research, there have been many cases that 
have become the waves of research fashions. In the AD case, it has been over a 
hundred years since Alois Alzheimer described the disease and great amount of data 
has been collected over the course. Despite of the progressively increasing mass of 
the data, there is no single target or a treatment to overcome the disease. Current data 
suggest the crucial role of erroneous cleavage of Amyloid Precursor Protein (APP) 
and hyperphosphorylation of Tau protein without the certainity of which comes first 
chronogically. Still, other molecular pathways including cell cycle regulation are also 
associated relatively recent with AD and some other neurodegenerative diseases. 
Understanding the simultaneous or chronogical molecular events that trigger and 
govern the major pathologies that cause the disease is immensly important to develop 
a certain treatment.       
1.2.2 A Model for Neurodegeneration: Alzheimer’s Disease 
AD was first described at 1902 by Alois Alzheimer, MD, through post-mortem 
observations on one of his patients. Dr. Alzheimer located abnormal clumps (now 
called amyloid plaques) and tangled bundles of fibers (now called neurofibrillary 
tangles) in hippocampal regions. Currently, these plaques and tangles in the brain are 
considered as the histopathological markers of AD. The pathological findings of AD 
are senile plaques that accumulate between nerve cells (β-amyloid plaques), 
neurofibrillary tangles (hyperphosphorylated tau proteins) and regression or 
retraction of dendrites. Systemically, hippocampus is reduced 47% in volume and 
amygdala is decreased 26% in volume, cell density is reduced by 75% at 
hippocampal and entorhinal regions.  
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AD is the most common type of dementia which accounts for an estimated 60–80% 
of all dementia cases. It manifests itself with difficulty in remembering names and 
recent events with the addition of apathy and depression as clinical symptoms. Later 
symptoms include impaired judgement, disorientation, confusion, behavioral 
changes, difficulty in speaking, swallowing and walking [6]. 
 
Figure 1.1: Alzheimer’s Disesase pathology. Hallmarks of AD are amyloid plaques 
and hyperphosphorylated tau (neurofibrillary tangles, NF), (ahaf.org). 
 
AD has two forms; familial form (FAD) which comprise 6% of all cases and 
sporadic form (SAD) that comprise 94% of all cases reported. FAD has been 
characterized by overexpression of APP and presenilin 1 and 2 gene mutations at the 
early onset and the mutated Apolipoprotein 4 (APOE4) allele at the late stage of 
progression. It is crucial to point out that Down Syndrome patients have a 
chromosome 21 trisomy and APP gene is located on the 21th chromosome. The 
trisomy leads its overexpression of this gene in these patients. Therefore, generally 
elder people develop AD but people with Down Syndrome also develop an early AD 
pathology if they pass their 35-40th age [7].  
 5
The sporadic form of the disease is thought be developed and progressed by 
environmental effects such as pesticides, exposure to heavy metals or free radicals 
that cause oxidative stress. However, the exact cause remains unknown and it is now 
a  known fact that the prevelance of the disease is increasing [7].  
Presenilin 1 (PS1) and Presenilin 2 (PS2) are important determinants of gamma-
secretase activity responsible for proteolytic cleavage of APP. Besides, PS1 and PS2 
localize at the nuclear membrane and interact with interphase kinetochores and 
centrosomes. It is also suggested that PS1 and PS2 also play a role in chromosome 
organization and segregation [8]. Point mutations in the PS1 gene result in a selective 
increase in the production of the abberantly cleaved amyloidogenic peptide amyloid-
beta (1-42) by proteolytic processing of APP [9]. 
Cell cycle abnormalities have been also associated with AD. Post mortem studies 
have reported detecting neurons in different stages of cell cycle yet never in Mitosis 
(M) phase [10]. These data suggest the presence of apoptotically induced cell death 
in the course of abnormal cell cycle re-entry and progression in the course of the 
disease. Adding to that, Alzheimer’s Disease is not the only neurodegenerative 
disorder associated with abnormal cell cycle re-entry and the common 
pathobiological mechanisms underlying of neurodegeneration are also associated 
with abberant cell cycle dynamics. Most importantly, certain manipulations to 
produce taupathies in animal models of neurodegeneration or wild type animals 
manifest with abnormal incomplete cell cyle re-entry leading cell death eventually 
[11-12].  
1.2.3 Cell Cycle Regulation in Mitotic Cells 
Cell cycle is the life cycle of a cell from the point that the cell is born to the point 
where it becomes two daughter cells. This process is divided into phases that are 
mainly, Gap Phase 1 (G1), Synthesis Phase (S), Gap Phase 2 (G2) and Mitosis Phase 
(M) and Gap Phase 0 (G0) where cells cease division. The first three phases are 
regarded as the "Interphase" to indicate the period between two divisions of the cell. 
M Phase is organized as a group of sub-phases that are Prophase, Metaphase, 
Anaphase and Telophase where chromosomal condensation, positioning and 
alignment and finally segregation occur. All the process usually takes from 30 
minutes (cells during embryonic development) up to 48 hours mainly varying in 
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different cell types. In the average human life, there are about 1016 cell divisions 
taking place.  
The cell cycle can be triggered by many different events. Basically, the critical ratio 
between volume of the cell and its surface area comes to a point that the whole 
surface tension cannot support the growing volume and this event initiates the 
sequence of intracellular signaling activities that trigger cell division phases. At the 
molecular level, the whole process is more complicated comprising the involvement 
of mitogenic factors and auto-protection mechanisms. 
 
Figure 1.2: Stages of cell division. DNA is labeled with DAPI (blue) and 
microtubules are shown (green) in sub-phases of M phase (adapted 
from Yong Wan et al). 
The cell cycle regulation is the orchestration of complex events that lead to the 
division of the cell. Therefore, the cell cycle orchestration is the regulatory network 
that orchestrates the sequence and timing of cell cycle phases. Above-mentioned 
series of biochemical switches initiates progression through the three major 
regulatory checkpoints of the cell cycle where entry into mitosis is controlled and 
regulated. The first checkpoint defines the entry into the cycle in late Gl to check the 
DNA damage; S phase checkpoint where improper spindle formation and 
unreplicated DNA is controlled and lastly the G2/M transition checkpoint again for 
DNA damage control.   
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Figure 1.3: Phases of cell cycle (art by Jane Wang).  
The main components of the cell cycle orchestration are cyclin-dependent kinases 
(Cdks). While a cell progresses through the cell cycle, sudden changes in the 
enzymatic activities of Cdks lead to changes in the activation states of proteins that 
control cell cycle processes through phosphorylation state. Concentrations of Cdk 
proteins are fixed during the whole cell cycle phases. Progressions and changes in 
their activity depend on fluctuations in the levels of the regulatory subunits called 
cyclins that bind to Cdks and stimulate their catalytic activities. Different cyclin 
types are produced at different cell cycle stages and form varying cyclin-Cdk 
complexes. Cyclin concentrations are highly important throughout the cell cycle. The 
activity of cyclin-Cdk complexes are further modulated by phosphorylation and the 
fluctuations in the levels of Cdk inhibitor proteins.  
Entry into a new cell cycle begins when signals from external (mitogens) or/and 
internal (systems related to cell growth and cell volume/surface area ratio) initiate the 
events that starts the expression of G0/G1, Gl/S and S/G2 transition related cyclin 
genes [13]. 
Cyclins are a diverse family of proteins that function by binding and activating 
members of the Cdk family proteins. Most cyclins display dramatic changes in 
concentration during the cell cycle, which help to generate the oscillations in Cdk 
activity that regulates orchestration of the cell cycle regulatory and control system. 
Cyclin concentrations are regulated primarily by changes in cyclin gene expressions 
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and degradation of cyclins by proteolysis. It is important to note that cyclins, like 
cyclin dependent kinases, are involved in a number of metabolic processes other than 
cell cycle control. Cyclins related to cell cycle control can be divided into four 
classes, based on the timing of their expression and their roles in cell cycle. These 
classes are the Gl/S cyclins, S cyclins and M cyclins that are directly involved in the 
control of cell cycle events and progression through phases, and lastly the Gl cyclins 
that takes role in the control of cell cycle entry in response to extracellular initiators 
[13].  
Activity of Gl phase Cdks are negatively regulated by Cdk-inhibitors that bind 
directly to Cdks or to Cdk-cyclin complexes. According to their structural properties, 
Cdk inhibitors are grouped into two families, INK4 and Cip/Kip. The INK4 family 
the main inhibitors of Cdk4, consists of four members that are; pl6INK4a, pl5INK4b 
pl8INK4c and pl9INK4d which can all inhibit cyclin D associated proteins. The Cip/Kip 
(Cdk interacting protein/kinase inhibitory protein) family consists of three proteins 
that are; p21Cip1, p27Kip1 and p57Kip2 which share a homologous inhibitory domain 
necessary for binding of Cdk4 and Cdk2 complexes. Compared to the INK4-family, 
they have a wider inhibition specificity.  
Primary step to initiate the cell cycle is the introduction of mitotic signals that result 
from ligand required activation of both integrins and/or growth factor receptors. The 
sequential progression through the Gl, S, G2 and M phases of the cell cycle is driven 
by the sequential activation of Cdks, which is controlled through positive and 
negative regulators. Each phase has its own cyclin-Cdk complex responsible for 
progression through the phase. Positive activation of Cdks are mainly triggered by 
the accumulation of cyclins, and regulated in a concentration dependent manner. 
Resulting Cdk activities determine whether mitogenic signals will be conveyed 
downstream inducing phosphorylation of the key substrates required for progression 
through Gl and entry into the next phase [14]. The major function of Gl phase 
kinases is to phosphorylate the Retinoblastoma (Rb-pRb) protein.  
Rb is the key element taking role as an inhibitor of progression through Gl phase. 
Activation of cyclin D dependent Cdks (Cdk4/6) initiate Rb phosphorylation in mid-
G1 phase of cell cycle. At this stage cyclin E-Cdk2 becomes active and 
phosphorylates Rb on additional sites. S phase and G2 phase Cdks that are activated 
later during the cell cycle maintain Rb in hyperphosphorylated form. Rb is coupled 
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with EF2, a transcription factor, suppressing the genes required for initiation and 
progression of cell cycle. High levels of RB phosphorylation leads to release of E2F, 
initiating the cell cycle [15]. In quiescent cells such as neurons, Rb is 
hypophosphorylated and E2F bind specifically to the hypophosphorylated form of 
pRb, to act as a proliferation inhibitor. Resetting the pRb-E2F complex occurs in M-
phase of cell cycle completing the phase [16]. In AD, increased immunoreactivity for 
hyperphosphorylated pRb and E2F has also been shown [17]. 
Triggering of the cell cycle by mitogenic compounds is initiated through Cdk 
activation by cyclin D1, which is the positive regulator of Cdk4/6. Additionally, 
activation of cyclin E which is the positive regulator of Cdk2, together with the 
repression of Cdk-inhibitors of Cip/Kip family (p21, p27 and p57), the negative 
regulators of Gl Cdks also take place at this phase [18]. Cyclins D1 and E are major 
downstream targets of signaling pathways involved in mediating structural plasticity 
such as Integrin, Catherin, Wnt signaling or many others. As a result, these signaling 
pathways regulate plasticity of the cell and cell cycle activation.  
 
  
 
Figure 1.4: Cdk inhibitors, Cip/Kip and INK family proteins. Here shown that 
Cip/Kip family has a wider inhibition specifity (left). Activation of next 
phase cyclin-Cdk complexes is regulated in a concentration dependent 
manner (right) [19].    
 
Progression of Cdk activity is followed in late G1 by an increase in cyclin E-Cdk2 
complex activity. The Cdk2-cyclin E complex is responsible for the Gl/S transition 
but also regulates centrosome duplication for the S phase. Cdk2 induces Cdk4 to 
complete Rb phosphorylation and initiates the degradation of p27. At this point, the 
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cell cycle is irreversibly committed to enter the S-phase. As cells transit the S-phase, 
ubiquitination and proteolysis of cyclin E occurs. During S-phase, cdk2-cyclin A 
phosphorylates a variety of other proteins regulating DNA replication [20]. 
 
  
Figure 1.5: Cyclin-Cyclin Dependent Kinase complexes. Each cyclin-Cdk complex 
is specific to a cell cycle phase (left). Restriction point (R) indicates the 
hyperphosphorylation of Retinoblastoma protein, the cell is no longer 
affected by extracellular signals from that point on (right) [19].  
 
At the S/G2 transition, Cdkl interacts and couples with cyclin A. During late G2, 
Cdk2–cyclin B (Mitosis Promoting Factor, MPF) triggers the G2/M transition, and 
cyclin A is ubiquitinated and degraded resetting the system for the next cycle.  At 
this point, cell enters a quiescent state called G0 phase for a period. After the 
completion of cell division the mitogens are withdrawn and Cyclin D1 is down-
regulated causing a release of a pool of Cip/Kip proteins that induce Gl phase arrest 
through inhibition of cyclin E-Cdk2. p21Cip1 also associates with PCNA, a subunit of 
DNA-polymerase delta, suggesting an additional mechanism through which p21Cip1 
can inhibit DNA synthesis [16]. It is crucial to note that, activation of each phase is 
dependent on the proper progression and completion of the previous phase.  
Non-proliferative cells in multi-cellular organisms generally enter G0 phase and 
remain quiescent for long periods. This is most common for terminally differentiated 
cells as in case of neurons. G0 stop may also occur in response to DNA damage or 
non-stable extracellular environment. Some cell types such as parenchymal cells of 
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liver, kidney or muscle cells enter into G0 phase semi-permanently and are induced 
to divide again when a specific stimulus arrives [19].  
1.2.4 Cell Cycle Events in Central Nervous System 
Although the pathological markers of AD are amyloid plaques and neurofibrillary 
tangles, the exact role of these in signal transduction pathways and crosstalk of AD 
remains unknown. Recent studies showed that cell cycle abnormalities also represent 
an important pathological feature in AD [7]. The evidence suggests that failure in 
neuronal cell cycle regulation, leading to apoptosis may play a significantly 
important role in the patho-biological development of AD. Many studies have 
reported that a wide range of cell cycle proteins such as Cyclin D, Cyclin A, Cyclin 
E, Cyclin B, Cdk4, PCNA, Cdc2 and Ki67, with the addition of some of cell cycle 
inhibitors including p16, p21 and p105 are elevated in neurons in the affected regions 
of late stage AD patients, but not in same aged control individuals [10]. Until recent 
years, the presence of these cell cycle proteins is thought to be found only in actively 
mitotic cells. However, the potential for re-entering cell cycle in fully differentiated 
neurons is reported to take place in the presence of certain growth factors such as 
Fibroblast Growth Factor 2 (FGF2) [1].  
The potential of entering and finishing cell cycle through a cell divison of neurons 
has been a debate issue for the last decades. Since the neurons are regarded to be 
terminally differentiated, incapable for dedifferentiation and cell divison, the 
argument seemed to be a strong one till the recent findings regarding the detected 
cell cycle markers in CNS [10].   
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Figure 1.6: Cell cycle re-activation associated with neurodegeneration (A) A 
hippocampal neuron from an AD patient section showing cyclin B 
positive immunostaining [21]. (B) PCNA expressed in the cerebellar 
Purkinje cells of diagnosed Ataxia Telangiectasia (AT) patient. (C) In 
cortical neurons of the transgenic R1.40  mouse, which is an AD 
transgenic mouse model, cyclin A is positive. (D) PCNA is expressed 
in the cerebellar Purkinje cells of AT transgenic mouse model. (E) 
FISH analysis showing the hybridization signals from a specific locus 
in the R1.40 mouse genome, indicating that DNA replication has 
occurred in the hippocampal neurons [22]. (F) DNA replication also 
can be found in the Purkinje cells of AT [10; 23]. 
 
1.2.5 Cell Cycle Associated Cell Death in Neurons 
During the neurogenic period, cells divide rapidly in the region of the ventricular 
zone where most cortical neurons are generated. After leaving ventricular zone, 
neurons differentiate and begin their migration to their final location at the adult 
stage. During and after migration is complete, the neurons complete their structural 
and biochemical differentiation program. Before they have reached a certain state, 
any interruption of cell cycle control results in the neuron re-entering a cell cycle 
followed by death within hours. In a mature neuron, any mitotic stress or stimuli that 
induces neuron re-enter the cell cycle will lead to a state which is permissive, but not 
sufficient to lead to neuronal death which also suggests a presence of a therapeutic 
window for degerating neuron. It has been shown that the first affected areas by this 
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type of stress conditions are the hippocampal region and the olfactory bulb. These 
priviliged areas also the ones where neurogenesis only occurs in adult stage of life 
[24]. These areas are suggested to be more susceptible to respond mitotic stress. The 
studies indicate that cell cycle re-entry is an early event in AD. In fact, activation of 
cell cycle may even cause the tangle formation through hyperphosphorylation. It has 
also been shown that P25/Cdk5 complex that is mainly related to cell cycle 
regulation hyperphosphorylates tau reducing its ability of binding to microtubules 
[7].  
Among the cell cycle related genes, some are E2F-responsive genes encoding 
proteins. Therefore, Rb might have an important role because its activity is involved 
in neuronal cell death and linked to E2F. In actively dividing cells, E2F forms an 
inhibited complex with hypophosphorylated form of Rb in G0/G1 phase. Inactivation 
of Rb by phosphorylation leads to its release from E2F, allowing transcription of 
E2F-responsive genes and G1/S phase transition. In neuronal cells, Rb protein plays a 
crucial role in cell survival because its phosphorylation is tightly associated to 
neuronal death . 
 
 
 
Figure 1.7: Cell cycle related cell death in neurons [10]. 
 
It has been  shown that (Figure 1.7), During the developmental stages neuroplastic 
cells divide rapidly at ventricular zone. After that, neurons become permanently post-
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mitotic and begin their migration to their final location as discussed previously. It has 
been hypothesized that oxidative stress, inflammation and DNA breaks is required to 
push the process of cell death in these differentiated adult neurons [10]. 
1.2.6 Effects of APP Signaling Pathways on Cell Cycle Re-entry  
Amyloid Precursor Protein (APP) is thought to act as a signaling receptor and 
influence neuronal survival in many different ways. This idea originates from the 
data of the predicted amino acid sequence of APP, which suggests that APP is a type 
1 membrane protein consistent with the structure of a cell surface receptor. The data 
coming from a study that aimed to detect a protein which directly interact with APP, 
showed that there is a protein called APP binding protein 1 (APP-BP1) that interacts 
with APP from its cytoplasmic domain. APP-BP1 protein was shown to be essential 
for S/M transition of cell cycle. Therefore, it has been shown that overexpression of 
APP causes an increase in expression of APP-BP1 in lipid rafts. The accumulation of 
APP-BP1 in lipid raft causes a stress factor leading cell cycle re-entry and eventually 
neuronal apoptosis [7].  
1.2.7 Effects of P25/Cdk5 Complex on Cell Cycle Re-entry  
Only low level of the protein P25 is present in healthy CNS. However, in the CNS of 
people with Alzheimer's, P25 has significantly increased expression rates. P25 is 
actually a fragment of P35 protein that can be formed when a stroke or some other 
unknown event causes the parent protein, P35, to split. The newly created P25 acts 
very differently from the protein from which it was originated. Unlike the parent 
protein, P25 keeps accumulating in the CNS. It causes its most severe damage 
indirectly through the way it alters the behavior of an enzyme called Cdk5. When 
Cdk5 pairs with the original P35 protein, it makes sure that the neurons remain 
healthy and form the appropriate neuronal patterns. But when the P25 protein takes 
over, Cdk5 becomes overactive and leads to hyperphosphorylation of tau and 
neuronal apoptosis [25]. Transgenic mice that overexpress human P25 in the 
postnatal basal forebrain display brain atrophy, neuronal loss in a pattern that 
correlates with P25 expression. Cdk5 is also hyperactive in degenerating neurons in 
AD, most likely because of the pathological accumulation of the activator protein 
p25, a Calpain cleavage product of P35 that causes sustained activation and  
erroneous localization of Cdk5. It has been proposed that treatment of neurons with 
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amyloid-beta peptides triggers the pathogenic cleavage of P35 by Calpain, which 
becomes active by Ca+2 atoms, leading the production of P25 [7]. This event leads to 
sustained Cdk5 activity and tau hyperphosphorylation which is already associated 
with abnormal cell cycle re-entry.    
1.3 Pin1 (Peptidyl-prolyl cis/trans Isomerase (PPIase)) 
Pin1 is a member of the Parvulin family, one of the three groups (Cyclophilins, FK-
506 binding proteins (FKBPs) and Parvulins) within the peptidyl-prolyl cis-trans 
isomerase (PPIase) group of proteins [26]. Parvulin family proteins have a variety of 
functions that include modulating the assembly, folding, activation/inactivation and 
transport of essential cell proteins [27]. They can also regulate intracellular 
signalling, affect transcription, cell cycle progression and apoptosis by altering their 
target protein’s activity and/or stability [28].  
Pin1 was the first human parvulin to be found and it has been observed to be 
essential for regulation of mitosis. It is located on chromosome 19p13 in the genome. 
It binds to and isomerizes the peptidyl–prolyl bond in specific phosphorylated 
Ser/Thr-Pro motifs, iniciating conformational change in its target phosphoproteins. 
Pin1 has a molecular mass of 18,245 kDa and was first discovered in a yeast two-
hybrid system experiment through its interaction with NIMA (Never in mitosis A) 
kinase that is essential for progression through mitosis. It contains 168 amino acid 
residues forming two domains that both recognize the same phosphoSer-Pro or 
phosphoThr-Pro motif. Pin1 can affect a wide range of cellular activites since 
Ser/Thr-Pro motifs are specific phophorylation sites for a great number of protein 
kinases that take part in cell cycle machinery and signal transduction system. Most of 
the mitogen activated kinases (MAPKs) and all Cdks are included in the group of 
these proteins.   
 Pin1 comprises two main domains that are the N-terminal WW domain and a C-
terminal PPIase domain. The WW domain is a small protein-protein interaction 
domain present in a variety of cell signaling proteins unrelated to each other [29].  
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Figure 1.8: Ribbon and surface representations of the X-ray structure of Pin1 in a 
complex with the pSer-Pro dipeptide in the peptidyl–prolyl cis/trans 
isomerase (PPIase) domain [30]. 
 
In mitotic cells, Pin1 regulates the progression of the cell cycle by interacting with a 
very large number of cell cycle related phosphoproteins (Table 1). It has been 
hypothesized that the conformational change of mitotic phosphoproteins induced by 
cis/trans isomerization of prolines in response to phosphorylation may regulate the 
progression of the cell cycle phases which makes Pin1 a crucial player during the 
course of cell cycle [31].  
 
Figure 1.9: Convertion of conformation of target protein from cis to trans  
confirmation by Pin1 [32]. 
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Table 1.1: Pin1 substrate proteins and their functions (adapted from Lu, K.P., 2004) 
 
Pin1 Substrates Function 
 
Mitotic Proteins 
NIMA                                                                     
 
 
Mitotic kinase 
Cdc25 
Wee1 
Plk1 
Myk1 
Cdc27 
CENP-F 
Icenp 
Rab4 
Bcl-2 
NHERF-1 
KRMP1 
CK2α 
Mitotic phosphatase 
Mitotic kinase 
Mitotic kinase 
Mitotic kinase 
Anaphase promoting complex 
Kinetochore protein  
Inner centromere protein  
G protein 
Anti-apoptotic protein 
Na+/H+ exchanger regulatory factor 
Kinesin related protein 
Casein kinase IIα 
TopIIα   
Dab2  
 
Cytoskeletal Proteins 
Tau    
 
Transcription Factors 
Pol II 
C-jun 
Β-catenin 
P53 
NF-κB 
Cf-2 
NFAT 
Sin3-Rpd3 
hSpt5 
CyclinD1 
Ki67 
 
Apoptotic Proteins 
Bcl-2 
Bim-EL 
Topoisomerase IIα 
Endocytic adaptor molecule 
 
 
Microtubule binding protein 
 
 
RNA Polymerase II 
Transcription factor 
Transcription factor 
Transcription factor 
Transcription factor 
Transcription factor 
Transcription factor 
Histone deacetylase complex 
Transcription elongation factor 
G1/S cyclin 
Proliferation associated marker 
 
Anti-apoptotic protein 
Pro-apoptotic protein 
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Pin1 has major effects on its substrates, altering their activity, stability,  state of 
phosphorylation, interactions with other proteins and subcellular localization. Pin1 
both negatively regulates entry into mitosis and is required for normal progression 
through mitosis in human cells. Decline of Pin1 in Hela cells initiates mitotic arrest 
and nuclear fragmentation, whereas Hela cells overexpressing Pin1 arrest in the G2 
phase of the cell cycle, indicating that overexpression of Pin1 inhibits the G2/M 
transition [26]. These data also suggest a required dose dependent activity for Pin1 in 
cells in order to mediate their natural metabolic course.  
 
 
Figure 1.10: Intracellular functions of Pin1. Pin1 mediates cis/trans or trans/cis 
isomerization on specific target sites, thereby regulating protein 
conformation through phosphorylation between two distinct structures 
here shown for amyloid precursor protein (APP) visualized by nuclear 
magnetic resonance spectroscopy (NMRs). These conformational 
changes have major effects on phosphorylation signalling by 
regulating a variety of target activities [33].  
 
Many functions of Pin1 have been revealed through the characterization of its 
substrates and Pin1 knock-out studies. As shown in a number of studies, the effects 
of Pin1 on its target proteins often leads to same or similar results [30; 34-36] 
suggesting that its activity of isomerisation can function as a molecular timing 
mechanism [37]. 
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1.3.1 Pin1 in Signal Transduction and Cell Cycle Mechanisms 
As indicated before; Pin1 acts as a catalyst in multiple signal transduction pathways. 
Pin1 directly interacts a large number of mitosis specific phosphoproteins, many of 
which are also recognized by the phosphospecific mitosis marker MPM-2 antibody 
[38]. Pin1 also regulates the activity of some of these regulators. Many proteins that 
are phosphorylated by Cdc2 are also Pin1 substrates that are distributed at different 
mitotic stages [39], and Pin1 depletion leads to mitotic catastrophe [26; 40]. 
Therefore, it is suggested that Pin1 helps with the orchestratiton mitotic events 
following phosphorylation by regulating the function of many mitotic proteins. 
It is known that G2/M transition is mainly conducted by the activation of the cyclin 
B-Cdc2 complex. The activity of cyclin B-Cdc2 is negatively regulated via 
phosphorylation by the Wee1 and Myt1 protein kinases, and positively regulated by 
the dephosphorylation of Thr-14 and Tyr-15 by Cdc25 phosphatase enzyme [41]. 
When the Cdc2-cyclin B complex is phosphorylated it becomes inactive and cell 
division cannot occur. The activated phosphatase Cdc25 removes two phosphate 
atoms from Cdc2 activating it and the cell finally enters mitosis. Pin1 acts as a 
conformational switch, turning mitosis on and off through isomerization of the 
phosphoThr-Pro or phosphosSer-Pro amides of Cdc25, controlling whether Cdc25 
exists in an active conformation [42]. 
It has been shown Pin1 interacts with β-catenin, after β-catenin is phosphorylated in 
its Ser246 residue; thus, contributing to its translocation to the cell nucleus as well as 
to a decrease in its degradation mechanisms [43]. β-catenin is a key transcription 
factor downstream of the Wnt pathway and is negatively regulated by the tumor 
suppressor APC (Anaphase Promoting Complex), which sends nuclear β-catenin to 
the cytoplasm and causes its degradation [44]. Pin1 specifically binds to the pSer246-
Pro motif of β-catenin inhibiting its binding to APC, resulting in the nuclear 
accumulation and stabilization of β-catenin. Pin1 overexpression correlates with 
increased β-catenin levels in human breast cancer tissues, whereas β-catenin levels 
are decreased in the tissues of Pin1-null mice [43] suggesting a novel role for for 
regulating the β-catenin–APC interaction [30]. Moreover, Pin1 has shown to be 
directly bound to both, β- and δ-catenin, once they have been phosphorylated by the 
Cdk5/p35 complex.  
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Studies also indicate that the Cdk5/p35 protein kinase system is directly involved in 
the regulatory mechanisms of neuronal β- and δ-catenin [45]. Pin1 has also 
association with DNA damage response where the damage leads to p53 stabilization 
and accumulation, which is regulated by a proline residue directed phosphorylation 
and the ubiquitin ligase MDM-2 [46]. Pin1 has been shown to be an important 
regulator of p53 during the process. After DNA damage, Pin1 binds to 
phosphorylated p53 and increases its stabilization and transcriptional activity by a 
possible mechanism of inhibiting the binding of p53 to MDM-2 [30; 47-48].  
 
 
 
Figure 1.11: Pin1 in varying signaling pathways. (A) c-Jun phosphorylation induced 
by growth signals, (B) β-catenin phosphorylation by Wnt signals, (C) 
p53 phosphorylation by DNA damage (adapted from Lu et al., 2004). 
 
1.3.2 Pin1 in Cancer 
The link between Pin1 and cancer was first suggested by the studies showing the 
overexpression of Pin1 in cancer tissues [43; 49] and more extensive studies 
confirmed the prevalent overexpression of Pin1 in 60 different tumor types, most 
commonly in breast, brain, lung and colon cancers [50].  
(A) (B) 
(C) 
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Pin1 is an E2F target gene [51] and deregulation of the Rb/E2F signal transduction 
pathway is found in most human cancers [52], suggesting a crucial role in Pin1 
overexpression affecting the process [30]. The overexpression of Pin1 also closely 
correlates with other oncogenic targets, such as cyclin D1 and β-catenin [49]. Most 
importantly, Pin1 positively regulates the function of cyclin D1 at the transcriptional 
level and through post-translational modifications. In Pin1 knock-out mice cyclin D1 
levels and  phenotypes are similar to cyclin D1 null mice [36]. 
In tumors such as colon and breast cancer, β-catenin can be activated by mutations in 
the genes coding for APC elements or β-catenin [53]. However, β-catenin is 
upregulated in many other cancers where mutations are rarely observed indicating 
the possible presence of epigenetic effects. Pin1 overexpression correlates with 
increased β-catenin levels in human breast cancer, whereas β-catenin levels are 
reported to be decreased in the tissues of Pin1-null mice [43]. Therefore, Pin1 
dependent prolyl isomerization is a novel mechanism for regulating the β-catenin 
APC interaction [30].  
Cell cycle checkpoints in the regulatory pathway control the timing and order of 
crucial cell cycle processes such as DNA replication in S phase and chromosome 
segregation in M phase to make sure that the division and production fo daughter 
cells proceeds with high efficiency [54]. Errors at checkpoints results in genetic 
instability and can be an early step in the progression of cancer. Cdc25 was identified 
as a potential target of checkpoint control in human cells during the G2/M transition 
responding the DNA damage [55]. Therefore the investigation of Cdc25 activation 
during the G2/M transition might potentialy address a fundamental step 
understanding the cancer pathology [56].  
Pin1 substrates constitute large classes of enzymes with essential roles in both 
quiescent and dividing cells. The mechanisms of many of these reactions are 
biochemically similar, therefore targeting specific family members is not easy. The 
unique phosphorylation dependent PPIase reaction catalyzed by Pin1 on pSer/Thr-
Pro residues makes it a highly attractive target for anti-cancer drugs. Because of the 
essential function of Pin1, inhibition of this enzyme holds the potential to target only 
dividing cells making the continuously dividing cells of cancer particularly 
susceptible to Pin1 targeting drugs [56].  
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Additionaly, cellular levels of Pin1 does not oscillate during the cell cycle, the total 
cellular Pin1 concentration in Hela cells was estimated to be ~0.5 µM [42]. Still, 
Pin1 is found at higher levels in cycling cells compared to the non-dividing cells, 
making it a target primarily in the continuously dividing cancer cells. Pin1 
expression has also been associated with Vascular Endothelial Growth Factor 
(VEGF) expression, the primary player in angiogenesis. Through isomerization of 
the necessary transcription factors, Hypoxia-inducible Factor-α (HIF-1α) and 
Activating Protein (AP-1) which is formed by c-Jun, c-Fos, and JunB, that switches 
on the VEGF gene by binding its promoter region. It has been shown that 
overexpression of Pin1 in breast cancer cell lines also leads to overexpression of 
VEGF promoting the angiogenesis in mid-stage cancer progression [57].  
1.3.3 Pin1 in Alzheimer’s Disease and Related Neurodegenerative Pathologies 
Unlike the cancer case, Pin1 paradoxically appears to act in a neuroprotective 
fashion. Primarily, it was suggested that through its ability to upregulate expression 
of cyclin D1, Pin1 may facilitate G0/G1 transition in neurons which may lead 
eventually to neuronal dedifferentiation and apoptosis [58].  
It has been reported that Pin1 expression in AD hippocampus is largely restricted to 
degenerative neurons whereas; Pin1 immunoreactivity was shown to appear as 
cytoplasmic granules also showing an inverse accumulation patterns in AD 
hippocampus [59]. Another study reported an inverse correlation between Pin1 
expression and predicted neuronal vulnerability and actual neurofibrillary 
degeneration in AD brain [60], also showing that Pin1 was revealed to be protective 
against neurodegeneration indicating that Pin1 knockout mice displayed age-
dependent neuropathology that included accumulation of abnormal and 
hyperphosphorylated tau that formed tau filaments leading to neurodegeneration 
[60]. It was also suggested that p-tau and dephospho-tau exist in a dynamic balance 
in the normal CNS. When Pin1 neuronal levels are low, as in susceptible neurons in 
AD brain or in Pin1-/- mice, the cis/trans isomerization of p-tau might not happen, 
preventing its proper dephosphorylation and the restoration of its normal function 
[60]. 
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 It is shown that Pin1 conversion of p-Thr231 tau to its trans isomer both restores the 
ability of p-tau to sustain microtubule assembly [34] and also enables its 
dephosphorylation by PP2A, which is a proline directed phosphatase. These are also 
supported by the finding that down regulation of PP2A in rat cortical slices induced 
AD like hyperphosphorylation of tau [7; 61]. 
 
Figure 1.12: Pin1 in cancer and AD. Pin1 is prevalently overexpressed in human 
cancers and functions as a key catalyst for multiple oncogenic 
signaling pathways. By contrast, Pin1 expression in neurons inversely 
correlates with the predicted neuronal vulnerability in normal brains 
and with actual neurofibrillary degeneration in AD [30]. 
 
It is important to note that many animal models of AD depends on the transgenic 
overexpression of specific proteins such as β-amyloid precursor protein and tau 
mutants [62]. Pin1 knock out mice provided the only knock-out AD model for age 
dependent neurodegeneration [60]. Besides, increased proline directed 
phosphorylation of tau appears to promote tangle formation and neurodegeneration 
in AD model mice [63]. Studies trying to reveal the causes of down-regulation of 
Pin1 in AD leads to oxidate damage inhibiting it at protein level [4] and promoter 
sequence variations decrasing the expressional rates of it [64]. DNA sequence 
variation and mutation analysis of Pin1 reports that Pin1 is well conserved gene with 
a few sequence variations in exons 2 and 3 that have no effect on AD [65]. In 
addition to effects of Pin1 in tau pathologies, it has been also reported that it also has 
a role in amyloid precursor protein processing. It has been shown that Pin1 has 
strong effects on APP processing and Aβ production.  
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Pin1 binds to the phosphorylated Thr668-Pro motif in APP and accelerates its 
isomerization by over 1,000-fold, regulating the APP intracellular domain between 
two isomeric conformations. Besides it was also reported that Pin1 overexpression 
reduces Aβ secretion in cell culture, additionaly knockout of Pin1 increases Aβ 
secretion selectively increasing Aβ42. Therefore, Pin1 dependent isomerization 
regulates APP processing and Aβ production, and it is suggested that Pin1 
deregulation may link both tangle and plaque pathologies [66]. 
 
 
 
Figure 1.13:  Phosphorylation of threonine–proline motifs in tau and APP by Pin1. 
The process contributes to AD by promoting the formation of plaques 
and neurofibrillary tangles. Through converting cis isomers back to 
trans forms, Pin1 helps driving dephosphorylation of both proteins, 
preventing plaques and tangles. But loss or downregulation of Pin1 
would have the opposite effect. Pin1 is a crucial target in the course of 
explaining why both plaques and tangles are found in the AD brains 
(adapted by Rachel Eastwood from original courtesy of Kun Ping Lu). 
 
Pin1 can also inhibit the MPF of Cdc25, inducing mitotic arrest and apoptosis. 
Additionaly, Pin1 is also crucial for maintaining the stability of β-catenin, which was 
reported to function in the decision of precursors to proliferate or differentiate during 
mammalian neuronal development suggesting that β-catenin can regulate cerebral 
cortical size by controlling the generation of neural precursor cells.  
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The same study also suggests that β-catenin activation functions in neural precursors 
to influence the decision to re-enter the cell cycle rather than differentiate during the 
course of mamalian neural development [67]. Regulatory function of Pin1 over β-
catenin also make it crucial target in both early and late stages of mammalian life.  
1.3.4 Inhibitors of Pin1 
Pin1 is an attractive target regarding its association with cancer and 
neurodegenerative diseases [30]. Juglone, 5-hydroxy-1,4-naphthoquinone, derived 
from wallnut was reported to selectively inhibit Pin1 by modifying its sulfhydryl 
groups and the activities of other PPIase families is not affected by juglone [68].  
Juglone has been used in a number of studies depending on its function inhibiting 
Pin1 [69]. It was also shown to prevent Pin1 dependent up regulation of cyclin D1 in 
human neuroblastoma cells [7]. Juglone was reported to have a retractory effect on 
the axons of hippocampal neurons through its possible effects on microtubule 
polymerization. The same study also provides a link between oxidative stress related 
to the presence of quinones like juglone and microtubule impairment, neuronal 
dysfunction and death that are associated with Alzheimer-like pathologies [70].   
 
Figure 1.14: Effects of juglone on cultured stage 3 hippocampal neurons. Axonal 
retraction is observable at the 3,3µM juglone concentration (adapted 
form Santa-Maria et al., 2005). 
Pin1 has also shown to be efficiently inhibited by Aryl Indanyl Ketones [71] and D- 
phospho-Thr containing peptides [72] which may provide therapeutic potential for 
treating Pin1 related pathologies [73].  
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2.  MATERIALS AND METHODS 
2.1 Materials  
2.1.1 Animals 
Post-natal 0 (PN0), (on the day they were born) Sprague-Dawley rats were used for 
hippocampal dissection procedures. Rats were housed in a sterile environment under 
12 hrs light/12 hrs dark cycles. All the animals were handled with appropriate animal 
care and utilization procedures.   
2.1.2 Solutions and Buffers 
2.1.2.1 PBS 
1X PBS solution was prepared by using PBS tablets (Sigma-Aldrich, Cat. no: P4417) 
PBS was stored at room temperature. One tablet dissolved in 200 mL of distilled 
water yields 0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M 
sodium chloride, pH 7.4, at 25 °C. 
2.1.2.3 Hippocampus Dissection Medium 
To prepare Hippocampus Dissection Medium, 5 ml HBSS (Invitrogen, 14185), 0,5 
ml 1M HEPES (Invitrogen, 15630-080), 0,5 ml Penicillin-Streptomycin (Sigma, 
P4333) were mixed. Final volume was brought to 50 ml by addition of 44 ml ddH2O. 
Medium was filter sterilized with 0,2 µm Nalgene filter. Medium is usable for 15 
days in 40C. It was also kept on ice while working. 
2.1.2.4 Hippocampus Plating Medium 
To prepare Hippocampus Plating Medium, 45,92 ml Neurobasal Medium 
(Invitrogen, 12349-015), 1 ml B27 Supplement (Invitrogen, 17504-044), 0, 33 ml 
45% Glucose (Sigma, G8769), 0, 25 ml L-Glutamine (Invitrogen, 25030-164) and 
2.5 ml FBS (Biological Industries, 04-001-1) were brought up together. Final volume 
was 50 ml. After filter sterilization, medium was kept in 40C for 15 days. 
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2.1.2.5 Hippocampus Serum Free Medium 
To prepare Hippocampus Serum Free Medium, 48,42 ml Neurobasal Medium 
(Invitrogen, 12349-015), 1 ml B27 Supplement (Invitrogen, 17504-044), 0,33 ml 
45% Glucose (Sigma, G8769), 0,25 ml L-Glutamine were brought up together. Final 
volume was brought up to 45 ml. After filter sterilization, medium was kept in 40C 
for 15 days. 
2.1.2.2 Mounting Medium 
Mounting medium was prepared by bringing 0.106g N-Propyl gallate (Sigma, 
P3130), 5 ml 1x PBS and 45 ml glycerol (Sigma, G2025) together. It was vortexed 
very well and kept at 40C. 
2.1.5.6 Fixative 
Ice cold Methanol (Sigma-Aldrich, Cat no: 443476) was used for fixation purposes.  
2.1.2.7 Blocking Solution 
Blocking solution application is important to reduce unspecific bindings. To prepare 
1 ml blocking solution 100 µl goat (or donkey) serum and 10 mg BSA were 
dissolved in 1X PBS and filtered with 0.8µm Nalgene filter. The final concentrations 
of ingredients were 10% serum and 10 mg/ ml BSA. Blocking solution is usable for  
5 days when stored at 40C. 
2.1.2.8 L – Glutamine 
L-glutamine (Sigma- Aldrich, Cat no: G7513) is an essential amino acid that is a 
crucial component of culture media that serves as a major energy source for cells in 
culture. L-glutamine is very stable as a dry powder and as a frozen solution. 
However in liquid media or stock solutions, L – glutamine degrades relatively 
rapidly. For optimal cell performance, L-glutamine is usually added to the media 
prior to use.  
2.1.2.9 Juglone 
Juglone (Calbiochem, Cat. no: 420120), also called 5-Hydroxy-1,4-
Naphthalenedione (IUPAC) or 5-Hydroxynaphthoquinone, is an organic compound 
with the molecular formula of C10H6O3.  
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Other names for Juglone are Nucin, Regianin, NCI 2323, and Oil Red BS. In this 
study, juglone was used as a selective Pin1 inhibitor at protein level. 
0,5 mM Juglone Stock Solution was prepared by dissolving 4.35mg Juglone in 0,5ml 
100% DMS0 and the volume was brought up to 50 ml by adding dH2O. A second 
stock solution with the concentration of 50µM was prepared by adding 5 ml 0,5 M 
juglone solution into 45ml dH2O. Juglone solutions were used in cell culture 
applications by adding 140µl and 160µl of 50µM juglone into petri dishes in order to 
gain respectively 3,5µM and 4µM in final volume of 2ml for cell culture 
applications.   
 
Figure 2.1: Molecular structure of Juglone. 
2.2 Methods  
2.2.1 Dissection of the Hippocampus 
In this study, hippocampi were gained from post-natal 0 Sprague-Dawley rats by 
anesthetizing them in ice and collecting the brains into dissection medium 
immediately after birth. Hippocampi were collected under stereo microscope in 
laminar flow cabin by using sterile equipment and immediately put into sterile 
dissection medium prior to following steps of the protocol.  
When viewed from the midline in sagital section, the hippocampus forms a C in the 
hemispheres. After all the required hippocampi were lifted with the forceps and 
transfered to a dish containing hippocampus dissection medium, the hippocampi 
were cut into small pieces and transferred into 15ml conical centrifuge tube. 
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Figure 2.2: Detailed map of hippocampus in rat brain [74], and 3D localization of 
hippocampus in rat brain (adapted from John C. Fiala and Josef 
Spacek) 
 
Dissection of hippocampus and cortex from embryonic rat brains. The PN1 rat brain 
was cut into halves via the midline sagittal section. The halves were placed to have 
the cortex facing up. Meninges (arrows) were removed from the hemispheres with 
No.5 forceps by gentle pulling. While holding the brainstem, the cortex was flipped 
outward and cut off the midbrain.  
The hippocampus is visible on the inner surface of the forebrain and was removed 
with forceps or a microscissor. Cortex and hippocampus were separated. The 
fimbriae (arrowhead) on the concave side of the hippocampus were removed (open 
arrowhead) as described by Fath et al (Figure 2.3) [75]. 
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Figure 2.3: Hippocampus dissection (Here shown in mouse brain) 
• The volume was brought to 4.5 ml with hippocampus dissection medium. 
• 0.5 ml Trypsin 2,5% (Gibco #25095-19) and 0.25 ml DNase (Sigma #DN-25) (10 
mg/ml) were added into tube, tube was gently mixed and incubated in 370C water 
bath for 20 minutes. 
• Hippocampi pieces were settled to the bottom of the tube, and after the incubation 
trypsin and DNase were pipetted off. 
• Hippocampi pieces were rinsed 2 times for 5 minutes each with 5ml hippocampus 
plating medium.  
• 1ml warm hippocampus plating medium was added into the tube. 
• Trituration was done 6-7 times against the side of the tube with a firepolished 
Pasteur pipette. The medium was especially pushed out against the side of the tube to 
prevent frothing because the cells at an air-liquid interface can be lysed.  
 32
• Dissociation was completed, and the cell density was determined by using 
hemacytometer. 
Hemacytometer is a specially designed slide with a counting chamber 0.1mm deep 
and ruled in a grid pattern. After the density and proportion of the viable cells was 
determined the required amount of cells were taken and diluted. For transfection, we 
used 106 cells per dish. 
2.2.2 Immunostaining  
In this study, counterstaining method was used to determine the cellular localization 
of the target proteins.  
Neurons are adherent cells that need a surface that they can stabilize on. In order to 
provide that, cover slips were coated with poly-L-Lysine. Each cover slip was placed 
in a petri dish (2ml) and covered with poly-L-Lysine for 1,5 hrs. They were washed 
with PBS(1X) afterwards prior to the plating of the hippocampal neurons.  
 
Table 2.1: Primary and Secondary Antibodies Used for the Study 
Antibodies    Company 
 
Primary Antibodies 
Cyclin D1 (C20) (Rabbit polyclonal IgG) Santa Cruz (sc-717) 
Cyclin A (C 19)(Rabbit polyclonal IgG) Santa Cruz (sc-596) 
Cyclin B1(M 20) (Rabbit polyclonal IgG) Santa Cruz (sc-595) 
Anti β III tubulin (Mouse monoconal IgG) Promega (G7121) 
Ki67 (M 19) (Goat polyclonal IgG) 
Anti P tau (Rabbit polyclonal IgG) 
 
Secondary Antibodies 
AlexaFluor®647 goat anti rabbit IgG  
Alexa Fluor®488 goat anti mouse IgG 
Alexa Fluor®488 donkey anti goat IgG 
Alexa Fluor®647 donkey anti rabbit IgG 
 
Santa Cruz (sc-7846) 
Sigma (T8444) 
 
 
Invitrogen (A21245) 
Invitrogen (A11029) 
Invitrogen (A11055) 
Invitrogen (A31573) 
 
Prior to immunocytostaining, plating mediums were discarded, plates were washed 2 
times with PBS(1X) and cells were fixed using ice cold Methanol and incubated at -
200C for 15 min. Fixed cells were washed with PBS(1X) 3 times. 
• Antibodies were diluted in PBS (dilution ratio was 1:1000 for all primary 
antibodies). 
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• To remove any precipitates formed during storage, diluted antibodies were 
centrifuged at 10.000 rpm for 10 minutes at 40C. 
• 200 µl of 1o Ab solution was put on the cover slips that are containing fixed cells. 
• 1o Ab containing cells were incubated at 40C for overnight. During the staining 
period, the dishes were placed in a “humidified chamber,” a large petri dish 
containing moistened filter paper, which minimizes evaporation of the antibody. 
• 1o Ab was removed by vacuum carefully and dishes were washed by using PBS 3 
times for 5 minutes each. 
• Cells were blocked again for 1 hour at room temperature with goat blocking 
solution. 
• 2o Ab was diluted and centrifuged in the same way as 1o Ab (dilution ratio was 
1:1000). 
• 200 µl of 2o Ab solution was put on the cover slips incubated for 1 hour in 370C. 
Working in dark with 2o Ab is crucial to prevent fluorescent quenching. 
• Dishes were rinsed with PBS 3 times for 5 minutes each. 
• 6-7 drops of mounting medium was dropped onto the slides. 
• Cover slips were placed on the slides and fixed from the edges by using nail 
polisher. 
• Slides were visualized and analyzed by using confocal microscopy techniques. 
Image Analysis was performed by using LEICA TCS SP5 II Confocal Microscope at 
63X oil objective, images were taken at 1024x1024 resolution.  
2.2.3 Real Time PCR Analysis 
Real time PCR Analysis is mainly used to amplify and simultaneously quantify a 
targeted nucleic acid molecule. The method enables both detection and quantification 
of absolute number of cDNA copies or relative amount when normalized to an 
known amount of cDNA count. The main feature of real time PCR is that the 
amplified DNA can be detected as the reaction progresses in real time. There are two 
common methods available for detection of products in real time PCR. The first one 
uses a non specific fluorescent dye that intercalates with double stranded DNA (E.g. 
Cybergreen), and the second one uses sequence specific DNA probes that are labeled 
with a fluorescent reporter molecule which allows detection only after hybridization 
of the probe to its complementary DNA sequence. Real time PCR is generally 
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combined with reverse transcription to quantify messenger RNA and produce cDNA 
for the PCR reaction. 
 
Figure 2.4: Taq Man® Real Time PCR principle: 1) TaqMan® probes’ reporter 
fluorescence is quenched due to FRET when they are intact. 2) Probes 
and their complementary DNA sequence are hybridized at this point 
reporter fluorescence is still quenched. 3) The 5'-ends of the probes are 
degraded by the Taq polymerase releasing the fluorescent reporter 
which produces a signal measurable by the PCR detector (image 
courtesy of S. Jähnichen). 
2.2.3.1 RNA isolation and Reverse Transcription 
High Pure RNA Isolation Kit designed for small-scale preparations of RNA (Roche, 
Cat. No: 11828665001) was used for RNA isolation. RNA concentrations were 
measured by using The Invitrogen QubitTM Quantitation Platform with Quant-IT™ 
RNA BR Assay Kit (Cat. No: Q10210).  
RevertAid™ H Minus First Strand cDNA Synthesis Kit (Fermentas #K1631) was 
used to produce full-length first strand cDNA from RNA templates. Random 
hexamer primers were used to produce cDNA. All RNA concentrations were in the 
range of cDNA Synthesis Protocol requirements. Petri dishes were washed with PBS 
and cells were incubated with 1X Trypsin-EDTA solution at 370C prior to RNA 
isolation procedure.  
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2.2.3.2 Real Time PCR Reaction and Interpretation of the Results 
Roche LightCycler® 480 Real-Time PCR System with a 96-well plate reader and a 
Roche TaqMan® Probe System were used for all analysis. All the primers and 
TaqMan® probes were selected from Roche primer & probe library. For this study; 
cyclin D1, cyclin A, cyclin B1, Ki67 and Cdk4 probes and primers were used.  
Analysis and interpretation of results were performed by using “Relative 
Quantification” algorithm, which is a widely used method to present relative gene 
expression. This method, also known as the 2-∆∆CT method, mainly depends on the 
assumption that the efficiency of the PCR is close to “1” and the PCR efficiency of 
the target gene is similar to the internal control gene [76-77]. The method has an 
advantage of efficiency correction which is the PCR efficiency of the target and 
internal control genes are included in the equation accounting the differences in the 
efficiency between target and internal control [77]. It also comes with the ability to 
present data as ‘fold change’ in expression. Disadvantages of the method are mainly 
the assumptions of PCR efficiency must fit in order to have a realistic result or the 
PCR must be further optimized [77]. The algorithm is: 
 
(1) Fold change = 2-∆∆CT 
(2) 2-∆∆CT = [(CT gene of interest - CT internal control) treated sample 
- [(CT gene of interest - CT internal control) untreated sample)] 
 
The reaction volume was adjusted to 10µl with the following ingredients: 1µl Probe 
+ 1µl Forward Primer + 1µl Reverse Primer + 2µl of Template + 5 µl Reaction 
Mixture (provided by LC®480 Kit). 
2.2.4 Immunoblotting 
2.2.4.1 SDS Page  
Sodium-dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) allows 
separation of proteins according to their weights. As a first step, %12 Separating gel 
was prepared by mixing 4 ml of %30 Acrylamide, 2.5 ml of 1,5 M Tris pH 8.8, 100 
µl of %10 SDS, 100 µl of %10 APS, 8 µl of TEMED, and 3.3 ml of dH2O. 
Separating gel was transferred into SDS gel cassette by pipetting. A thin layer of 
isoprophanol was added onto the gel filling in the casette. The gel was let at room 
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temperature for 30 minutes for polymerization. Secondly, isopropanol in the cassette 
was discarded with a tissue paper until the upper part of the gel was free from the 
isopropanol. %5 stacking gel was prepared by mixing; 670µl of %30 Acrylamide, 
500 µl of 0.5 M Tris pH 6.8, 40 µl of %10 SDS, 40 µl of %10 APS, 4 µl of TEMED 
and finally 2.7 ml of dH2O. Stacking gel was added onto the separating gel in the 
cassette and left for 45 minutes. at room temperature for polymerization. 5µl of ~10 
mg/ml protein samples was mixed with 4X loading buffer and denatured at 95°C for 
5 minutes. ~20µl of each sample was loaded onto SDS-PAGE gel. SeeBlue® Plus2 
Pre-Stained Standard (Invitrogen Cat. no. LC5925) was used as protein ladder, 5µl of 
protein ladder was loaded into the first well. Approximately 15µg of total protein 
sample was loaded into each well. Electrophoresis was performed in Tris-Glycine 
running buffer at 100 V, for first 10 minutes and voltage was increased up to 120 V 
for 90 minutes.  
2.2.4.2 Western Blotting 
The protein samples were separated on SDS-PAGE according to their molecular 
weights and they were transferred to a nitrocellulose membrane and analyzed for 
presence of target proteins by wet blot transfer system, Trans-Blot® Electrophoretic 
Transfer Cell (BIO-RAD, 170-3910). Next, the membrane was incubated at room 
temperature overnight with blocking solution, %3 BSA in H2O. The membrane was 
washed with TBS-T at room temperature each for 10 min (TBS-T buffer: 90µl %0.05 
Tween 20 and 180ml TBS). Then, the membrane was incubated with primary 
antibody in blocking solution at room temperature for 2 hours. The first antibody 
blocking solution included 40µl of first antibody (200µg/ml) with 10ml blocking 
buffer (1:250). After primary antibody incubation, membrane was washed three 
times with TBS-T buffer at room temperature each for 10 mins. Secondary antibody 
solution comprised 2µl of HRP conjugated secondary antibody in 10ml (1:5000) %3 
BSA blocking solution. Membrane was incubated with secondary antibody for 1.5 
hours at room temperature. Amersham ECL Plus Western Blotting Detection 
Reagents (GE Healthcare, RPN2132) were used to obtain a chemiluminescent signal 
through the HRP/lumigen reaction. The membrane was incubated for 5 minutes in 
dark. Excess detection reagent was drained off by holding the membrane gently in 
forceps and touching the edge against a tissue. The blot was placed protein side down 
between fresh pieces of acetate in a cassette and air bubbles were gently smoothed 
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out. The membrane was placed protein side up, in the x-ray film cassette and 
differing exposure times were tried to gain the optimum results.  
2.2.5 Immunohistochemistry (IHC) 
Immunohistochemistry (IHC) is the process of determining the localization antigens 
in cells of a tissue section utilizing the principle of antibodies’ binding specificity to 
antigens in biological tissues. For this experimental step, 3-4 months old male 
Sprague-Dawley rats weighing 300 to 400 g were used to reveal the effects of Pin1 
inhibition via juglone. 0,1 mg/kg and 1 mg/kg juglone concentrations were used with 
the vehicle (1% DMSO) as test doses. Rats received intraperitoneal injections of 0,1 
mg/kg, 1 mg/kg and 1% DMSO as a vehicle for 20 days at sterile conditions with 
sufficient food and water supply and under normal day/night cycles. 
Deep anesthesia was induced by intraperitoneal injections of ketamine in the animals 
and surgical exposure of the heart and aorta was perfomed for each animal. a 
perfusion cannula through the left ventricle into the aorta was inserted and the 
cannula was clamped off to prevent backflow of the perfusion solutions. The right 
atrium was cut open and perfusing the animal with ice-cold saline was performed 
approximately with 100 ml saline. After that perfusion of the animal with 4% 
paraformaldehyde was perfomed with approximately 250 ml of paraformaldehyde. 
After an appropriate amount of fixative is perfused through the animal, the perfusion 
pump was stopped and the brain were dissected. Dissected brains were then 
immersion fixed for an additional 2 hours in 4% paraformaldehyde. Brains were 
removed from the fixative, rinsed in PBS and immersed into 25 mL 30% sucrose 
solution and remained in solution at 4°C for overnight.  
40µm brain sections were taken using cryostat and free floating technique was 
perfomed. Free-floating sections of rat brains were washed three times, 10 minutes 
each, in 1X PBS and were incubated at room temperature in 0.2% H2O2 for 20 
minutes to block the activity endogenous peroxidases which prevents DAB reaction 
at the last step of the experiment. The sections were then rinsed three times with 1X 
PBS, 10 minutes each. Following the rinsing, slices were pre-incubated for 2 hrs. at 
room temperature with 1% Normal Goat Serum (NGS)/PBS-Triton-X for blocking. 
Primary antibodies (Cyclin D1, Santa Cruz (sc-717), cyclin A Santa Cruz (sc-596))  
were diluted in PBS-T containing 1% NGS (1:10000) and left for overnight 
incubation at 4°C. The next day sections washed with PBS-T for three times for 10 
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minutes. Sections were then incubated with the biotinylated secondary antibodies 
(1:400) diluted in a solution of PBS-T containing 1% NGS for 1 hour at room 
temperature. The sections were again washed with PBS-T for 3 times, 10 minutes 
each. Following to this step, brain sections were incubated in avidin-biotin 
peroxidase complex (1:100 in PBS-T; ABC Solution/Vectastain Elite ABC Kit, 
Vector Labs, Burlington, CA). Slices were prepared according to Vectastain Elite 
DAB protocol. Immunoreaction was visualized by placing the sections in a staining 
solution containing 0.04% 3,3'-diaminobenzidine, 0.06% nickel sulfate, and 0.06% 
H2O2 for 3-10 mins. The slices were mounted, coverslipped and observed under a 
light microscope. The anatomical assesment was perfomed by referencing the 
anatomical markers such as neocotex or corpus callosum within the observed area of 
the section. 
2.2.6 Image Analysis by ImageJ 
In order to obtain total fluorescence per cell and corrected integrated density for each 
cell, background subtraction was performed from raw images taken under same 
microscopy settings, by using ImageJ Software. Detailed information for corrected 
integrated density analysis, has been documented at www.cooperlab.wustl.edu under 
“Lab Methods, Protocols & Operations” section. 
2.2.7 LDH Cytotoxicity Assay 
LDH test is a colorimetric assay for the quantification of cell death and cell lysis, 
based on the measurement of lactate dehydrogenase (LDH) activity released from the 
cytosol of damaged cells into the supernatant. Roche LDH Cytotocity Kit (Catalog 
No. 11644793001) was used to perform the assay. There are several controls in order 
to perform the test: 1) Background control that provides information about the LDH 
activity that is contained in the assay medium. The absorbance value obtained from 
this control was subtracted from all other values. 2) Low control, that provides 
information about the LDH activity released from the untreated normal cells that 
means the spontaneous LDH release. 3) High control, that provides information 
about the maximum releasable LDH activity in the cells that show the maximum 
LDH release. 690-492nm wavelengths were used to determine the absorbance value 
from juglone treated samples and controls.   
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2.2.8 Statistical Analysis 
All statistical analysis was performed by using GraphPad Instat3 statistical analysis 
software. Kolmogorov–Smirnov test was used to determine the Gaussian or normal 
distribution of the data. t-test was performed for the data following normal 
distribution and Mann-Whitney U test was used for was performed for the data set 
that were not following normal distribution. P value under 0,05 was considered 
significant for each analysis. 
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3.  RESULTS  AND DISCUSSION 
3.1 Real Time PCR Analysis of Cell Cycle Marker Proteins’ Expressions 
Cell cycle marker genes were analyzed by Real time PCR to reveal the changes in 
their expressional profiles after Pin1 inhibition in hippocampal cells by incubation 
with juglone (Ct values are shown in Appendix A.1).   
 
Figure 3.1:  Mean Expressional Levels of Cell Cycle Related Genes. Untreated cells 
have a relative expressional value of “1” in each gene that was 
analyzed. 
The results indicate that between the range of 3,5 and 5µM juglone concentration at 
3 hours of incubation period, there is a nearly 1,5 fold increase in cyclin D1 
expression relative to the cyclin D1 expression in the untreated control group (p 
value is 0.0238, p<0,05). There was not a statistically meaningful increase in cyclin 
A (p value is 0.3996, p>0,05), cyclin B1 (value is 0.3803, p>0,05) and Ki67 (p value 
is 0.0983, p>0,05) expressions compared to untreated control cells (Figure 3.1).   
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In order to optimize real-time PCR conditions for neuronal cells, serum free plating 
medium was used which eliminates the proliferation of non-neuronal cells in the 
culture purifying the outcome of real-time PCR analysis. 
Real Time PCR analysis indicates the mRNA levels of the target genes. These results 
were also compared with immunocytochemistry, immunohistochemistry and western 
blotting analysis providing information at proteomic level.    
3.2 Effects of Pin1 Inhibition on Cell Cycle Markers: Immunocytochemistry 
Analysis  
The primary purpose was to observe the effects of Pin1 inhibition on the cell cycle 
associated proteins, cyclin D1, cyclin A, cyclin B1 in Post-natal 0 hippocampal 
neurons after 2,5 and 3 hours of incubation within the range of  3,5 and 5µM juglone 
at 370C at this step of the study.  
AD-like features such as axonal retraction and up-regulation of cell cycle markers 
were observable. A change in cell morphology was observed to be dramatic, 
suggesting neuronal loss for the given experimental conditions. β-III tubulin, a 
neuron specific marker was used for observing cytoskeletal changes related to 
microtubule dynamics. Slightly higher concentrations of juglone, especially 4µM, 
were more effective creating the AD-like features in terms of more increase in the 
levels of cell cycle markers and the effects on microtubular dysregulation. 
Cyclin D1 expression was observed to be up-regulated for the neurons which were 
incubated with 3,5µM and 5µM juglone for 2,5 hours and 4µM juglone for 3 hours at 
370C, 5%CO2 (Figure 3.2). Axonal retraction and a change in cell morphology were 
visible depending on the β-III tubulin distribution suggesting a cytoskeletal 
disintegrity. In the control group, the cells were incubated under normal cell 
culturing conditions and they were observed to preserve their morphological features 
(β-III tubulin (green)) with a very low expressional rate of cyclin D1 (red) (Figure 
3.2). Cyclin D1 expression (red) and lack of β-III tubulin can be seen in non-
neuronal cells (Figure 3.2).  
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Figure 3.2: Cyclin D1 expression and morphological changes in 3,5µM juglone for 
2,5 hours and 4µM juglone for 3 hours incubations, β-III tubulin 
(green), cyclin D1 (red), DAPI (blue) (A); Cyclin D1 and β-III tubulin 
expression in non-neuronal cells (B). 
 
 
A 
B 
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 Figure 3.2: (cont’d) Integrated pixel analysis for Cyclin D1 expressions, (p<   
0.0001, considered extremely significant) (C).   
 
Cyclin A expression was observed in both juglone treated hippocampal cells and 
untreated control group (Figure 3.3). Cyclin A was also located at nucleus in both 
treated and untreated neurons suggesting another possible function for it aside from 
being a cell cycle regulatory protein. In non-neuronal cells, cyclin A was observed in 
both nucleus and in cytoplasm (Figure 3.3). Nuclear localization of cyclin A was 
observed to be more condensed in the nucleus after incubation of hippocampal cells 
in 4µM juglone for 3 hours. Additionally, cells were observed to be more globular in 
shape suggesting cytoskeletal disintegration.  
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Figure 3.3: Cyclin A expression in untreated cells, at 4µM juglone for 3 hours of 
incubation and non-neuronal cells, β-III tubulin (green), cyclin A (red), 
DAPI (blue) (A); Integrated pixel analysis for cyclin A expression, (p 
value is 0.7342, considered not significant) (B).  
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An increase in cyclin B1 expression was also observable in 3,5µM juglone treated 
hippocampal cells (Figure 3.4). Moreover, there was no observable cyclin B1 
expression in untreated control cells (Figure 3.4). Cyclin B1 localization was both 
nuclear and cytoplasmic when treated with 4µM juglone for 3 hours (Figure 3.6). 
Still, cyclin B1 was localized in the nucleus rather than the cytoplasm. The same 
cytoskeletal morphology was also evident in the treated cells. No visible cyclin B1 
expression was observed in the untreated cells (Figure 3.6).  
 
 
 
Figure 3.4: Cyclin B1 expression in untreated cells, at 3,5µM juglone for 2,5 hours; 
4µM juglone for 3 hours and 4µM juglone for 12 hours of incubation, 
β-III tubulin (green), cyclin B1 (red), DAPI (blue) (A). 
A 
 47
 
 
Figure 3.4: (cont’d) Integrated pixel analysis for cyclin B1 expression, (p <  
0.0001, considered extremely significant) (B). 
 
Effects of Pin1 inhibition on phosphorylated tau, ptau, regulation and on 
proliferative marker Ki67 were also investigated. Tau protein is mainly required for 
the stabilization of microtubule structure in the axons and it mainly drives this 
function via phosphorylation. It is a highly soluble microtubule associated protein 
interacting with microtubules providing integrity, whereas ptau protein loses its 
activity and disassociate from the microtubules in the axons disrupting the 
microtubule network. Phosphorylation of tau can form self-assembly of the tau 
proteins and forming the tangle structure that is seen in AD pathology. Pin1 is 
reported to regulate and restore the function of ptau activity and depletion of Pin1 
activity is suggested to promote ptau self-assembly [34]. It is crucial to note that tau 
is not present in dendrites where more flexibility is needed. The results indicate that 
ptau is accumulating the cell body and nuclear regions after Pin1 inhibition by 4µM 
juglone for 3 hours (Figure 3.5). Microtubule disruption was also visible like in the 
other experimental groups. In the untreated control group that was incubated under 
normal cell culturing conditions, low levels of ptau is visible in the axons of the 
neurons (red) (Figure 3.5). 
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Figure 3.5: Ptau expression in untreated cells, 4µM juglone for 3 hours, β-III tubulin 
       (green), ptau (red), DAPI (blue) (A); Integrated pixel analysis for ptau 
       expression, (p < 0.0001, considered extremely significant) (B). 
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Effects of Pin1 inhibition on ptau regulation and on proliferative marker Ki67 were 
also investigated. Tau protein is mainly required for the stabilization of microtubule 
structure in the axons and it mainly drives this function via phosphorylation. It is a 
highly soluble microtubule associated protein interacting with microtubules 
providing integrity, whereas phosphorylated tau (ptau) protein loses its activity and 
disassociate from the microtubules in the axons disrupting the microtubule network. 
Phosphorylation of tau can form self-assembly of the tau proteins and forming the 
tangle structure that is seen in AD pathology. Pin1 is reported to regulate and restore 
the function of ptau activity and depletion of Pin1 activity is suggested to promote 
ptau self-assembly [34]. It is crucial to note that tau is not present in dendrites where 
more flexibility is needed. The results indicate that ptau is accumulating the cell 
body and nuclear regions after Pin1 inhibition by 4µM juglone for 3 hrs (Figure 3.5). 
Microtubule disruption was also visible like in the other experimental groups. In the 
untreated control group that was incubated under normal cell culturing conditions, 
low levels of ptau is visible in the axons of the neurons (red) (Figure 3.5). 
 
Figure 3.6: Ki67 expression in untreated cells, 4µM juglone for 3 hrs, β-III tubulin 
                  (red), Ki67 (green), DAPI (blue) (A). 
A 
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Figure 3.6: (cont’d) Integrated pixel analysis for Ki67 expression, (4µM juglone 3 
hours: p value is 0.0012, considered very significant; 4µM juglone 12 
hours: p value is 0.0444, considered significant) (B). 
 
Changes in Ki67 expression were also significant; yet, there was only a slight up-
regulation in expression when neurons were incubated with 4µM juglone for 12 
hours. Ki67 was mainly located in cell bodies (Figure 3.6) As a proliferation marker 
Ki67 is only expressed in cycling cells and it is also involved in RNA synthesis of 
cell cycle related proteins. Presence of Ki67 in neural progenitor cells is known to be 
ceased after differentiation process.  
Our results indicate that cyclin D1 was up-regulated at both RNA and protein levels; 
cyclin B1 was up-regulated at protein level according to immunocytochemistry 
analysis; there was no change in cyclin A levels neither in RNA nor in protein levels, 
yet a more condensed nuclear localization was observed for cyclin A, D1 and B1 
after Pin1 inhibition by juglone. A dramatic change in cell morphology depending on 
the possible disruption of microtubule structure in the cells was also clearly visible. 
A change of localization and an increase in protein level for ptau was observable. A 
slight up-regulation of Ki67 was also observable at 4µM juglone incubation for 12 
hours. Accordingly, the evidence is pointing an up-regulation of cell cycle marker 
proteins prior to AD-like neuronal loss. 
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3.3. Western Blotting and Immunohistochemistry (IHC) Analyses  
In order to confirm the immunocytochemistry and real time PCR results Western 
Blotting analysis was performed. The results for cyclin D1 are consistent with 
immunocytochemistry data and real time PCR.  
 
 
Figure 3.7: Western Blotting indicates an increase in cyclin D1 levels. 
Immunohistochemistry analysis was performed to reveal the effects of Pin1 
inhibition via juglone on adult individuals in terms of the changes in expression of 
cell cycle markers. The results indicate that there is an up-regulation of cyclin D1 
especially in cortical areas in the adult rat brain after 20 days of 0,1 mg/kg and 1 
mg/kg juglone injection (Figure 3.8). Whereas, there cyclin A was evident in both 
juglone treated and untreated groups, mostly localize in entorhinal cortex and dentate 
gyrus (Figure 3.9). This evidence was also consistent with immunocytochemistry and 
RT-PCR for cyclin A, again suggesting a role for it in neurons apart from its role in 
cell cycle. 
Overall comparison of the results shows a consistent up-regulation for cyclin D1, and 
stable expression for cyclin A with a condensed localization. cyclin B1 was not up-
regulated according to RT-PCR but an up-regulation was observed in 
immunocytochemistry analysis. Ptau was up-regulated with a more condensed 
localization at the cell body. LDH Cytotoxicity results were also showing that at 3 
hours of juglone incubation, the toxicity was %0,43 and at 12 hours of juglone 
incubation it was %8,9. Therefore, the observed effects are not due to juglone 
toxicity for the given concentrations and incubation periods. Additionally, there was 
a slight increase in Ki67 levels according to immunocytochemistry but not in RT-
PCR results.  
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Figure 3.8: Immunohistochemistry analysis for cyclin D1 expression in rat brains 
       after receiving 0,1 mg/kg and 1mg/kg. An increase in expression and 
       localization of cyclin D1 can be observed.  
 
Figure  3.9: Immunohistochemistry analysis for  cyclin D1 expression in rat brains 
                  after receiving 0,1 mg/kg and 1mg/kg. 
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Inhibition of Pin1 via its selective inhibitor juglone causes an up-regulation of cell 
certain cycle related genes in both RNA and protein levels. Ki67 was observed to be 
more increased at protein level and not in RNA level according to real time PCR 
results that needs further investigation. Cyclin D1 was seen to be up-regulated 
whereas cyclin A was observed to be stable in all experimental analysis. Still, stable 
expression and nuclear localization of cyclin A in hippocampal neurons; suggest a 
distinct role for it besides its role in cell cycle regulation in mitotic cells. 
Table 3.1: Comparison of Real Time PCR, Western Blotting, Immunocytochemistry 
                and Immunohistochemistry Results 
 
 
 
Accumulation of cyclin B1 in post-mitotic neurons under excitotoxicity has been 
reported before and it was also claimed that nuclear accumulation of cyclin B1 in 
neurons results in neuronal loss. Additionally, cyclin B1 accumulation in AD brain 
has also been shown and presence of an interaction between P25/Cdk5 complex, 
Cadherin1 protein and cyclin B1 stabilization in excitotoxicity conditions have been 
reported [78]. It is also evident that Cdk5 has a modulatory effect on Pin1 related to 
its function in axonal outgrown and neuronal migration processes. Therefore, Pin1 
inhibition by juglone may be provoking cyclin B1 accumulation by an indirect 
fashion. Besides, cyclin B1 is a substrate of Anaphase promoting 
complex/cyclosome, a ubiquitin ligase complex which destabilizes cell cycle related 
proteins and regulates axonal growth, synaptic plasticity and neuronal survival in 
differentiated neurons. The processes related to synaptic plasticity could be 
especially important to understand “the post mitotic neuron” regarding the common 
signal transduction pathways regulating both cell cycle and synaptic plasticity.  
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Lastly, cyclin B1 up-regulation and accumulation through Pin1 inhibition via juglone 
seems to be a strong candidate promoting neuronal loss. Similarly, up-regulation of 
cyclin D1 expression was associated with neuronal loss in granule neurons [79]. It 
can be suggested that Pin1 inhibition via juglone produces an AD-like pathology 
depending on the up-regulation of cell cycle marker proteins rather than an entry into 
a normally regulated cell cycle in hippocampal neurons. It also disrupts cytoskeleton 
as an indirect effect of functional inhibition in Pin1.            
Significant amount of studies have collected evidence supporting the idea that 
aberrant cell cycle regulation in neural cells play a crucial role in varying 
neurodegenerative events in the CNS. Yet, it is still not clear that if cell cycle re-
entry is a protective response or lethal event in post-mitotic neurons. Increasing 
number of observations confirm that cell cycle re-entry is becoming to be a 
breakpoint point in neurodegenerative pathologies. The common notion about 
neurons regarding their degree of differentiation and their lack of capacity to divide 
is now under question. The expression of cell cycle markers in the adult CNS has 
always been a matter of debate.  
Although neurons are terminally differentiated cells, they express a wide range of 
cell cycle proteins and are showed to be capable of replicating their DNA completing 
the S phase [80]. Moreover, it was recently reported that, cell cycle regulator proteins 
serve diverse post-mitotic functions that comprise various neurodevelopmental 
stages including neuronal migration, axonal elongation, axon pruning, dendrite 
morphogenesis, and synaptic maturation and plasticity [81]. It was also reported that 
hippocampal neurons can divide in presence of FGF2 in cell culture conditions [1]. 
Another study, which was mainly conducted at physiological level, reported 
observing division of hippocampal neurons in presence of Ouabain [2], adding that 
for many cells it was only nuclear division suggesting a restrictive role for the 
cytoskeleton. However, it has also been confirmed by many studies that abnormal 
cell cycle re-entry or up-regulation of cell cycle related actors in response to some 
mutations or extracellular stress factors leads neuronal apoptosis.  
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Many causes have been linked to neurodegenerative cell cycle dysregulation process 
such as; excess amount of mitogenic signals [10], changes in microtubule dynamics 
[11], CNS injury [82], presence of oxidative stress that inhibit neuroprotective 
proteins [4] and even the presence of oncogenic signals have been suggested to 
promote neuronal cell cycle re-entry [80]. It is important to note that the latter study 
also suggests that the reason for the absence of neuronal division in vivo and tumors 
of neuronal origin, would reflect the impossibility of a fully mature neuronal 
cytoskeleton to revert to a mitosis ready configuration [80].  
One specific study introduces the "Dr. Jekyll and Mr. Hyde Concept" regarding the 
neuronal plasticity regulation and its possible link to cell cycle related neuronal loss, 
adding that after being quiescent cells, differentiated neurons become able to use 
molecular mechanisms that were primarily developed to control proliferation, 
alternatively begin to control synaptic plasticity. Therefore, the existence of these 
influential pathways in a neuron puts it at risk by erroneously converting signals 
related to regulation of synaptic plasticity into orientational signals that will re-
activate the cell cycle [83]. Hence, understanding the cell cycle events occurring in 
neurons comprises importance not only because of the possibility to solve the 
neurodegenerative puzzles but also to comprehend the mitotic potentials of neurons.  
Besides, it is also crucial to comprehend the orchestration of events cascading in cell 
cycle re-entry for developing therapeutic options for neurodegenerative pathology 
related to cell cycle dysregulation. Of course, timing and specificity are important 
considerations in the development of drugs effective in neurodegenerative conditions 
such as AD. Because aberrant cell cycle re-entry appears to be possibly, the earliest 
neuropathological event detected so far [21], therefore, countermeasures targeting 
this will likely to be more effective than therapies targeted at downstream events [7]. 
Hopefully, many ongoing studies regarding the cell cycle regulation in varying types 
of cells are will gather information that will introduce brand new perspectives into 
our understanding of this complex machinery and its elusive link to 
neurodegeneration. 
Pin1 is relatively a recent discovery that has been introduced cell cycle research 
related to both neurodegeneration and cancer. It rapidly became a potential target, 
which stands at a key point molecule regarding abnormal cell cycle re-entry in 
neurodegeneration. Besides, because of its remarkably high levels in wide variety of 
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cancer lines such as breast, brain, lung and colon cancers it became attractive for 
research as a therapeutic target. Pin1 has unique influences on cell cycle machinery 
being at a key position where it affects other key molecules during the course of cell 
cycle regulation. As in neurodegeneration case, Pin1 is becoming a more attractive 
subject providing the only knock-out mouse model that can produce AD-like 
pathology [60]. 
 
 
 
Figure 3.12: Representation of cell cycle re-activation in AD neurons that leads to  
neurodegeneration [84].  
 
Other available models depend on over-expression of certain genes. Besides, Pin1 
also holds a potential to be regarded as a neuroprotective protein through its function 
to regulate cyclin D1 [7]. Pin1 has observed to interact with many proteins that have 
previously been associated in cell cycle regulation (cyclins and Cdks), proliferation 
(β-catenin) [43], apoptosis (P53) [47].     
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4.  CONCLUSION AND RECOMMENDATIONS 
This study is the first attempt to reveal the effects of Pin1 inhibition on cell cycle 
marker proteins in hippocampal neurons according to our literature search. It also 
aims to demonstrate the effects of Pin1 inhibition on the structure of cytoskeleton in 
accordance to the state of the neuronal cell cycle. As the immunocytochemistry 
results indicates, inhibition of Pin1 by its selective inhibitor, juglone alters the 
expressions and cellular localization of cell cycle related marker proteins, also 
producing an AD like cellular pathology. All the cyclins that were observed (D1, A, 
B1) were up-regulated prior to neuronal loss (Figures 3.1-3.7). Additionally, 
cytoskeletal dynamics were affected dramatically and axonal retraction was observed 
suggesting a disintegration of microtubules related to the loss of indirect functions of 
Pin1 protein. Pin1 inhibition also affected localization and cellular presence and ptau 
possibly indicating the loss of neuroprotective role of Pin1 due to its inhibition 
(Figure 3.8). There was also a slight increase in Ki67, which is a proliferative marker 
only expressed in active cell cycle phases (Figure 3.9). These results holds 
importance due to their potential to indicate a direct association with Pin1 inhibition 
to up-regulation of cell cycle related markers and formation of neurodegenerative 
pathology in hippocampal neurons, that were shown to be the primary susceptible 
cell group in AD. 
Real time analysis were in coherence with microscopy analysis with a slight shift that 
needs further experiments with more purified culturing conditions from non-neuronal 
cells. Still, an increase in the levels of especially cyclin D1 is consistent with 
immunocytochemistry, western blotting and IHC results. Cyclin A expressions were 
also consistent indicating a stable expression rate for all the conditions analyzed.           
Investigation of Pin1 manipulations is substantially important for both 
neurodegeneration and cancer studies. Being a novel phosphorylation signaling 
protein that regulates diverse cellular processes, Pin1 deregulation can play a crucial 
role in the pathology of cancer and AD. Therefore, Pin1 has become an attractive 
therapeutic target. Further studies may include over-expression Pin1 in hippocampal 
neurons to elucidate the mechanism where it takes role as a neuroprotective protein 
 58
and its influence on regulation of cell cycle regulation in post-mitotic neurons. It 
could be speculated that over-expression of Pin1 in neurons would also result in 
neuronal loss due to its possible expressional dose dependent behaviors.  
Most importantly, elucidating Pin1’s role as a link between neurodegeneration and 
cancer holds significant importance understanding underlying mechanism of both. In 
order to achieve this, a potential tool of research is Neuroblastoma, which is a type of 
tumor originated from faulty differentiated neural progenitor cells of sympathetic 
nervous system and adrenal glands.  
Neuroblastoma cells comprise clinical importance in terms of their origin. For 
instance, when they are stimulated with either retinoic Acid or NGF (Nerve Growth 
Factor) they differentiate into neuron-like cells. Being a neural progenitor originated 
tumor also makes it an attractive target for cell cycle and neuronal differentiation 
research. As a target, alterations of Pin1 may trigger responses related to cell cycle 
alterations and differentiation in Neuroblastoma cells regarding the native functions 
of Pin1 protein. Neuroblastoma cells provide an exceptional model for investigation 
of Pin1 regulated cell cycle and cellular differentiation in both neurodegeneration 
and cancer processes. Thus, molecular manipulations of Pin1 may provide insights to 
the possible link between two age related pathologies, which has been evaluated 
from distinct perspectives.   
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APPENDICES 
 
 
Ct values from Real Time PCR Analysis: 
  
Ct Ct 
 
Ct Ct 
 
Ct Ct 
  
3,5µM  
J1 Control 1  
3,5µM 
J2 
Control 
2  5µM J1 
Control 
1 
 CYCD1 23,96 27,68 23,83 22,72 23,62 27,68 
CYCA 29,54 29,35 27,56 27,09 28,06 29,35 
CYCB1 15,95 18,08 27,33 25,93 15,94 18,08 
KI67 28,09 30,02 28,84 28,1 27,6 30,02 
  
ACTIN 26,09 27,65 15,73 14,02 25,93 27,65 
GAPDH 19,59 22,04 20,62 19,37 19,33 22,04 
  
Geomean 22,6076 24,6861 18,0098 16,4793 22,3881 24,6861 
 
Ct Ct 
 
  5µM  J2 Control 2 
 CYCD1 23,27 22,72 
CYCA 27,58 27,09 
CYCB1 27,32 25,93 
KI67 27,97 28,1 
  
ACTIN 15,77 14,02 
GAPDH 20,35 19,37 
  
Geomean 17,9142 16,4793 
 
Ct Ct 
 
Ct Ct 
 
Ct Ct 
  4µM  J1 N1 4µM J2 N2 4µM J3 N3 
 CYCD1 26,77 27,09 28,225 27,06 27,2 27,26 
CYCA 30,45 30,955 31,535 30,55 32,05 31,11 
CYCB1 27,475 27,35 28,825 27,615 27,685 27,16 
KI67 28,385 28,595 29,525 27,85 28,325 28,2 
  
ACTIN 17,765 18,24 18,985 17,725 17,485 18,055 
GAPDH 21,205 21,505 22,575 21,16 21,455 21,235 
  
Geomean 19,4089 19,8053 20,7023 19,3665 19,3685 19,5805 
  
 APPENDIX A.1 :  
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Fold Change 4µMJ1 Control 1 
 CYCD1 0,948421 1 
CYCA 1,078181 1 
CYCB1 0,696695 1 
KI67 0,878796 1 
Fold Change 4µMJ2 Control 2 
CYCD1 1,125683 1 
CYCA 1,275268 1 
CYCB1 1,091113 1 
KI67 1,265055 1 
 
   
 
Fold Change 4µMJ3 Control 3 
CYCD1 0,897199 1 
CYCA 0,450001 1 
CYCB1 0,599986 1 
KI67 0,791686 1 
  
   Fold Change 3,5µM J1 Control 1 
CYCD1 3,117955 1 
CYCA 0,207546 1 
CYCB1 1,036 1 
KI67 1,022 1 
 
  
   
 
Fold Change 3,5µM J2 Control 2 
CYCD1 1,3384 1 
CYCA 2,0856 1 
CYCB1 1,095 1 
KI67 1,73 1 
  
   
 
Fold Change 5µM J1 Control 1 
CYCD1 3,3916 1 
CYCA 0,49723 1 
CYCB1 0,8962 1 
KI67 1,2328 1 
   
 
 
 
 
 
 
 
 
Fold Change 5µM J2 Control 2 
CYCD1 1,85 1 
CYCA 1,925 1 
CYCB1 1,365 1 
KI67 2,958 1 
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